ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University to better understand if the CD8+ T-cell responses from COVID-19 recovered individuals still recognize the major SARS-CoV-2 variants. Out of 45 mutations assessed from the SA, UK and Brazil variants, only one mutation within the SA variant, B.1.351 Spike protein overlapped with a single low-prevalence CD8+ epitope T cell response. These findings suggest that virtually all the anti-SARS-CoV-2 CD8+ T-cell responses induced by COVID-19 infection in our recovered individuals should recognize these newly described variants.
These findings were published in:
Open Forum Infectious Diseases